Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

PMD-026 for the Treatment of Myelofibrosis, Myelodysplastic Syndromes or Myeloproliferative Neoplasms

Trial Status: active

This phase I trial tests the safety, side effects, and best dose of PMD-026 in treating patients with myelofibrosis myelodysplastic syndromes (MDS) or myeloproliferative neoplasms (MPNs). Myelofibrosis, MDS and MPNs are types of blood cancer in which scar tissue forms in the bone marrow. This tissue causes normal production of blood cells (red blood cells, platelets, and a type of white blood cell called granulocytes) to be disrupted. PMD-026 is an enzyme inhibitor. It may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth, which inhibits cancer cell proliferation, differentiation, and survival.